Conformational properties of HIV-1 gp120/V3 immunogenic domains.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Medicinal Chemistry

• Publication date

  2005-05-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/0929867054038982PMID 15974987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Simple Electrostatic Interaction Mechanisms in the Service of HIV‐1 Pathogenesis

  2004cited by this paper
• Prevalence of Alleles Associated with HIV Resistance in Russia

  2004cited by this paper
• Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

  2004cited by this paper
• Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

  2004cited by this paper
• Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity.

  2003cited by this paper
• Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.

  2003cited by this paper
• Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

  2003cited by this paper
• Enhanced: The Need for a Global HIV Vaccine Enterprise

  2003cited by this paper
• The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor

  2002cited by this paper
• Ionic interaction of the HIV-1 V3 domain with CCR5 and deregulation of T lymphocyte function.

  2002cited by this paper
• Tyrosine-sulfated Peptides Functionally Reconstitute a CCR5 Variant Lacking a Critical Amino-terminal Region*

  2002cited by this paper
• Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1.

  2002cited by this paper
• Identification of Conserved and Variable Structures in the Human Immunodeficiency Virus gp120 Glycoprotein of Importance for CXCR4 Binding

  2002cited by this paper
• HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

  2002cited by this paper
• Dys-regulation of effector CD4+ T cell function by the V3 domain of the HIV-1 gp120 during antigen presentation.

  2001cited by this paper
• An overview of the determinants of CCR5 and CXCR4 co-receptor function.

  2001cited by this paper
• The global impact of HIV/AIDS

  2001cited by this paper
• V3 induces in human normal cell populations an accelerated macrophage-mediated proliferation--apoptosis phenomenon of effector T cells when they respond to their cognate antigen.

  2001cited by this paper
• Fluorescence resonance energy transfer analysis of CCR-V64I and SDF1-3'a polymorphisms: prevalence in southern Spain hiv type 1+ cohort and noninfected population.

  2001cited by this paper
• Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution.

  2001cited by this paper
• Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor*

  2001cited by this paper
• Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes

  2001cited by this paper
• Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype

  2000cited by this paper
• New targets for inhibitors of HIV-1 replication

  2000cited by this paper
• Mechanisms of HIV-associated lymphocyte apoptosis.

  2000cited by this paper
• Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry*

  2000cited by this paper
• Allelic Distribution of CCR5 and CCR2 Genes in an Italian Population Sample

  2000cited by this paper
• Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities*

  2000cited by this paper
• Energetics of the HIV gp120-CD4 binding reaction.

  2000cited by this paper
• Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

  2000cited by this paper
• Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4.

  2000cited by this paper
• High frequency of the HIV-1 protective CCR5 delta32 deletion in native Estonians.

  2000cited by this paper
• A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry*

  2000cited by this paper
• N-Linked Glycosylation of CXCR4 Masks Coreceptor Function for CCR5-Dependent Human Immunodeficiency Virus Type 1 Isolates

  2000cited by this paper
• A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

  2000cited by this paper
• A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints.

  2000cited by this paper
• Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1

  2000cited by this paper
• NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding.

  2000cited by this paper
• Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived from Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-Induced Anti-HIV Neutralizing Antibodies

  1999cited by this paper
• Mutagenesis of CXCR4 Identifies Important Domains for Human Immunodeficiency Virus Type 1 X4 Isolate Envelope-Mediated Membrane Fusion and Virus Entry and Reveals Cryptic Coreceptor Activity for R5 Isolates

  1999cited by this paper
• Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications.

  1999cited by this paper
• Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5

  1999cited by this paper
• Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

  1999cited by this paper
• Increased Association of Glycoprotein 120-CD4 with HIV Type 1 Coreceptors in the Presence of Complex-Enhanced Anti-CD4 Monoclonal Antibodies

  1999cited by this paper
• Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

  1999cited by this paper
• Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.

  1999cited by this paper
• Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry?

  1999cited by this paper
• Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function*

  1999cited by this paper
• Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions*

  1999cited by this paper
• A cis proline turn linking two β-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide

  1999cited by this paper
• Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.

  1999cited by this paper
• Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses

  1999cited by this paper
• Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein*

  1999cited by this paper
• Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions

  1999cited by this paper
• Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

  1999cited by this paper
• T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure

  1999cited by this paper
• Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection

  1999cited by this paper
• Marked Increase in Anti-HIV Activity, as Well as Inhibitory Activity against HIV Entry Mediated by CXCR4, Linked to Enhancement of the Binding Ability of Tachyplesin Analogs to CXCR4

  1999cited by this paper
• A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

  1999cited by this paper
• CCR5 HIV-1 Coreceptor Activity

  1999cited by this paper
• A new classification for HIV-1

  1998cited by this paper
• A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

  1998cited by this paper
• Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines

  1998cited by this paper
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100

  1998cited by this paper
• A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry

  1998cited by this paper
• Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.

  1998cited by this paper
• AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

  1998cited by this paper
• Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

  1998cited by this paper
• Use of Murine CXCR-4 as a Second Receptor by Some T-Cell-Tropic Human Immunodeficiency Viruses

  1998cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans

  1998cited by this paper
• T-Tropic Human Immunodeficiency Virus Type 1 (HIV-1)-Derived V3 Loop Peptides Directly Bind to CXCR-4 and Inhibit T-Tropic HIV-1 Infection

  1998cited by this paper
• CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.

  1998cited by this paper
• Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.

  1998cited by this paper
• Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1

  1998cited by this paper
• HIV entry and tropism. When one receptor is not enough.

  1998cited by this paper
• A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

  1998cited by this paper
• Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.

  1998cited by this paper
• The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 A resolution: implications for T cell and NK cell recognition.

  1998cited by this paper
• Introduction: HIV co-receptors solve old questions and raise many new ones.

  1998cited by this paper
• CXCR4 Sequences Involved in Coreceptor Determination of Human Immunodeficiency Virus Type-1 Tropism

  1998cited by this paper
• Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 (HIV-1) V3 Loop Chimeras from a Combinatorial Library Induce Potent Neutralizing Antibody Responses against HIV-1

  1998cited by this paper
• And the Best Picture is — the HIV gp120 envelope, please!

  1998cited by this paper
• Small molecule inhibitor of HIV‐1 cell fusion blocks chemokine receptor‐mediated function

  1998cited by this paper
• Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4

  1997cited by this paper
• HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.

  1997cited by this paper
• Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1

  1997cited by this paper
• Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.

  1997cited by this paper
• Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.

  1997cited by this paper
• HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor

  1997cited by this paper
• Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding

  1997cited by this paper
• Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent

  1997cited by this paper
• A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB)

  1997cited by this paper
• NMR structure of the principal neutralizing determinant of HIV-1 displayed in filamentous bacteriophage coat protein.

  1997cited by this paper
• Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.

  1997cited by this paper
• CC Chemokine Receptor 5-Mediated Signaling and HIV-1 Co-receptor Activity Share Common Structural Determinants

  1997cited by this paper
• Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor

  1997cited by this paper

• Unraveling clinical outcomes of long-term cART treatment in HIV-1 patients with or without the Brazilian GWGR motif in the V3 loop

  2024cites this paper
• Global Variability of V3 Loop Tetrapeptide Motif: a Concern for HIV-1 Neutralizing Antibodies-based Vaccine Design and Antiretroviral Therapy

  2021cites this paper
• Structural dynamics of V3 loop in a trimeric ambiance, a molecular dynamics study on gp120-CD4 trimeric mimic.

  2014cites this paper
• Subtype B Was the Dominant Strain Among HIV Type 1 Infections Except for the Population of Men Who Have Sex with Men in Harbin City, China

  2013influential citation
• Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120

  2013cites this paper
• Peptide Inhibition of HIV-1

  2012cites this paper
• Humanized Mice as a Model to Study Human Viral Pathogenesis and Novel Antiviral Drugs

  2012cites this paper
• Evidence of HIV-1 gp120/V3 — CCR5 peptide complex organization in vitro

  2011cites this paper
• Recent Advances inDe NovoProtein Design

  2011cites this paper
• Hepatitis C virus, human immunodeficiency virus and pseudomonas phage PS5 triad share epitopes of immunogenic determinants

  2010cites this paper
• NMR evidence of charge‐dependent interaction between various PND V3 and CCR5 N‐terminal peptides

  2009cites this paper
• Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

  2008cites this paper
• Peptide inhibition of HIV-1: current status and future potential.

  2008cites this paper
• Overcoming the Key Challenges in De Novo Protein Design: Enhancing Computational Efficiency and Incorporating True Backbone Flexibility

  2008cites this paper
• HIV-1 gp120/V3-derived epitopes promote activation-induced cell death to superantigen-stimulated CD4+/CD45RO+ T cells.

  2007cites this paper
• A new de novo approach for optimizing peptides that inhibit HIV-1 entry

  2007cites this paper
• Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of the interaction with chemokine receptor CCR5.

  2007cites this paper
• Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity

  2006cites this paper
• HIV-1 infection: is it time to reconsider our concepts?

  2006cites this paper
• HIV entry inhibitors: a new generation of antiretroviral drugs

  2005cites this paper